Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; TSHEPISO Study Team. Dooley KE, et al. Among authors: haas dw. J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31. J Infect Dis. 2015. PMID: 25081933 Free PMC article.
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. Luetkemeyer AF, et al. Among authors: haas dw. Clin Infect Dis. 2015 Jun 15;60(12):1860-3. doi: 10.1093/cid/civ155. Epub 2015 Feb 26. Clin Infect Dis. 2015. PMID: 25722197 Free PMC article.
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P; IMPAACT P1078 (TB APPRISE) Study Group Team. Gausi K, et al. Among authors: haas dw. Clin Pharmacol Ther. 2021 Apr;109(4):1034-1044. doi: 10.1002/cpt.2044. Epub 2020 Oct 16. Clin Pharmacol Ther. 2021. PMID: 32909316 Free PMC article. Clinical Trial.
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE; AIDS Clinical Trials Group A5338 Study Team. Haas DW, et al. Pharmacogenet Genomics. 2022 Jan 1;32(1):24-30. doi: 10.1097/FPC.0000000000000448. Pharmacogenet Genomics. 2022. PMID: 34369424 Free PMC article. Clinical Trial.
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C; ACTG 5267 Study Team. Dooley KE, et al. Among authors: haas dw. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62. doi: 10.1097/QAI.0b013e3182410503. J Acquir Immune Defic Syndr. 2012. PMID: 22126739 Free PMC article. Clinical Trial.
257 results